Dizal Pharmaceutical(SH:688192) 智通财经网·2025-06-12 07:55Core Viewpoint - The company, DIZH Pharmaceutical (688192.SH), is set to present significant research advancements on its first-in-class drugs, GoliXitini (GoliXitini Capsules) and DZD8586, at the upcoming EHA and ICML conferences, focusing on their efficacy and safety in treating hematological malignancies [1][2]. Group 1: GoliXitini Research Findings - GoliXitini is being studied for maintenance therapy in patients with peripheral T-cell lymphoma (PTCL) who have achieved remission after first-line systemic treatment, showing potential to maintain and enhance anti-tumor efficacy with manageable safety [1] - The drug has demonstrated encouraging anti-tumor efficacy and good safety in various clinical studies, including those involving first-line treatment with the CHOP regimen for PTCL and real-world studies for relapsed/refractory T-cell large granular lymphocyte leukemia (r/rT-LGLL) [1] Group 2: DZD8586 Research Findings - DZD8586 has shown an objective response rate (ORR) of 84.2% in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have previously undergone multiple treatments, including those with classic BTK resistance mutations [2] - The safety profile of DZD8586 is controllable, with no observed drug-related bleeding, atrial fibrillation, or major cardiac risks in clinical settings [2] - Latest data from a Phase II clinical study of DZD8586 as a monotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) will also be presented, indicating good anti-tumor efficacy and safety [2]